A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain. The registry was established with the following objectives: \[1\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \[2\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \[3\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \[4\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Screening for a panel of anti-neuronal antibodies via commercial assays
Timeframe: at recruitment
Screening for unknown anti-neuronal antibodies via immunofluorescence staining on fresh mouse brain (tissue-based assay, TBA)
Timeframe: at recruitment
Determination of the molecular weight of the antibody target
Timeframe: at recruitment
CSF cell count
Timeframe: at recruitment
CSF protein
Timeframe: at recruitment
CSF albumin
Timeframe: at recruitment
CSF glucose
Timeframe: at recruitment
CSF lactate
Timeframe: at recruitment
CSF IgG
Timeframe: at recruitment
CSF oligoclonal bands
Timeframe: at recruitment